Search

Your search keyword '"Stani, Simonetta"' showing total 29 results
Start Over Author "Stani, Simonetta"
29 results on '"Stani, Simonetta"'

1. Third national surgical consensus conference of the Italian Association of Breast Surgeons (ANISC) on management after neoadjuvant chemotherapy: The difficulty in reaching a consensus

Author

Zanotti, Simone, Ceccarossi, Virginia, Massaza, Lauretta, Cosentino, Luigi Marino, Amaturo, Giuseppe, Curcio, Annalisa, Bondioli, Paola, Meattini, Icro, Luca, Alessandro De, Garcia-Etienne, Carlos Alberto, Gala, Antonia, Thodas, Alexios, Lozupone, Antonia, Botticella, Maria Antonietta, Grassi, Massimo, Santoro, Valeria, Ala, Ada, Tessa, Cristina La, D'onghia, Giuliano, Carfora, Elisabetta, Cappelli, Sonia, Nunzi, Martina, Mastropietro, Tiziana, Meneghini, Graziano, Morichetti, Doriana, Sanna, Paola Angela, Pozzi, Giada, Soatti, Carlo Pietro, Pellegrini, Alba, Puccica, Ilaria, Frati, Sara, Leone, Alba Di, Giuliani, Giuliana, Conte, Anna Maria, Zamagni, Claudio, Seriau, Luca, Minischetti, Monica, Foroni, Moira, Valli, Mariacarla, Lippi, Andrea, Ravarino, Alberto, Giaccherini, Lucia, Calzolaro, Adele, Neri, Anna, Carli, Luciano, Mambelli, Laura, Prisco, Agnese, Di Marzio, Enrico, Venturini, Annalisa, Gattuso, Maria Ilaria, Sicignano, Margherita, Amabile, Maria Ida, Baldissera, Antonella, Sibilio, Andrea, Chiavilli, Stefano, Gennari, Roberto, Melina, Marica, D'aponte, Maria Luisa, Germano, Alessandro, Baldoni, Giulia, Santurro, Letizia, Busani, Massimo, Bonanni, Alessio, Tondo, Salvatore, Marchetti, Vania, Cassinotti, Michela, Serra, Margherita, Stani, Simonetta, Firpo, Emma, Grendele, Sara, Spolveri, Federico, Custodero, Olindo, Pellegrini, Francesco, Cremonini, Anna, De Tullio, Damiano, Sorbo, Grazia, Combi, Francesca, Aristei, Cynthia, Roncella, Manuela, Folli, Secondo, Nesi, Silvia, Gentile, Damiano, Burlizzi, Stefano, Galimberti, Viviana, Trapani, Anna, Curella, Luciano, Panizza, Pietro, Nanez, Jose Andres Diaz, Sgarella, Adele, Pensa, Anna, Gasperoni, Marco, Marino, Lorenza, Marzetti, Alice, De Rosa, Antonia, Borri, Filippo, Camilletti, Anna Chiara, Ruggieri, Annamaria, Andrulli, Angela Damiana, Silvia, Asioli, Terribile, Daniela Andreina, Accardo, Giuseppe, Patrone, Francesco, Raviele, Paola Rafaniello, Santini, Donatella, Costarelli, Leopoldo, Angelini, Lucia, Reitano, Renato, Polistena, Andrea, Palma, Enza, Santoni, Marcello, Magni, Carla, Cima, Simona, Foglietta, Jennifer, Minafra, Marina, Rizzo, Antonio, Milanesio, Michela Camilla, Giorgini, Sara, Grossi, Simona, Cumbo, Jacopo, Campanella, Barbara, Fante, Rossella, Pinta, Massimo La, Manna, Elena, Santini, Elena, Mascioni, Francesca, Teggi, Silvia, Galasso, Maria Grazia, Sanguinetti, Alessandro, Fenocchio, Daniela, Giacobbe, Felicia, Pellegrini, Alice, Papi, Simona, Pieroni, Marzia, Villa, Elisa, Querzoli, Patrizia, Guadagno, Elia, Perfetti, Alessandra, Balzarotti, Laura, Ciriotto, Davide, Guida, Giovanna, Canova, Elisa, Lunardi, Maria, Vignutelli, Patrizia, Apicella, Giuseppina, Natale, Maria, Ghilli, Matteo, Troilo, Vito Leopoldo, Rocco, Nicola, Schiavone, Alfonso, Ventimiglia, Fabrizio, Zarba Meli, Emanuele, Taffurelli, Mario, Caruso, Francesco, Gentilini, Oreste Davide, Del Mastro, Lucia, Livi, Lorenzo, Castellano, Isabella, Bernardi, Daniela, Minelli, Mauro, and Fortunato, Lucio

Published
2024
Full Text
View/download PDF

3. T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer

Author

Fabi, Alessandra, Alesini, Daniele, Valle, Enrichetta, Moscetti, Luca, Caputo, Roberta, Caruso, Michele, Carbognin, Luisa, Ciccarese, Mariangela, La Verde, Nicla, Arpino, Grazia, Cannita, Katia, Paris, Ida, Santini, Daniele, Montemurro, Filippo, Russillo, Michelangelo, Ferretti, Gianluigi, Filippelli, Gianfranco, Rossello, Rosalba, Fabbri, Agnese, Zambelli, Alberto, Leonardi, Vita, D’Ottavio, Anna Maria, Nisticò, Cecilia, Stani, Simonetta, Giampaglia, Marianna, Scandurra, Giusy, Catania, Giovanna, Malaguti, Paola, Giannarelli, Diana, and Cognetti, Francesco

Published
2018
Full Text
View/download PDF

4. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

Author

Di Lisa, Francesca Sofia, primary, Krasniqi, Eriseld, additional, Pizzuti, Laura, additional, Barba, Maddalena, additional, Cannita, Katia, additional, De Giorgi, Ugo, additional, Borella, Fulvio, additional, Foglietta, Jennifer, additional, Cariello, Anna, additional, Ferro, Antonella, additional, Picardo, Elisa, additional, Mitidieri, Marco, additional, Sini, Valentina, additional, Stani, Simonetta, additional, Tonini, Giuseppe, additional, Santini, Daniele, additional, La Verde, Nicla, additional, Gambaro, Anna Rita, additional, Grassadonia, Antonino, additional, Tinari, Nicola, additional, Garrone, Ornella, additional, Sarobba, Giuseppina, additional, Livi, Lorenzo, additional, Meattini, Icro, additional, D’Auria, Giuliana, additional, Vergati, Matteo, additional, Gamucci, Teresa, additional, Pistelli, Mirco, additional, Berardi, Rossana, additional, Risi, Emanuela, additional, Giotta, Francesco, additional, Lorusso, Vito, additional, Rinaldi, Lucia, additional, Artale, Salvatore, additional, Cazzaniga, Marina Elena, additional, Zustovich, Fable, additional, Cappuzzo, Federico, additional, Landi, Lorenza, additional, Torrisi, Rosalba, additional, Scagnoli, Simone, additional, Botticelli, Andrea, additional, Michelotti, Andrea, additional, Fratini, Beatrice, additional, Saltarelli, Rosa, additional, Paris, Ida, additional, Muratore, Margherita, additional, Cassano, Alessandra, additional, Gianni, Lorenzo, additional, Gaspari, Valeria, additional, Veltri, Enzo Maria, additional, Zoratto, Federica, additional, Fiorio, Elena, additional, Fabbri, Maria Agnese, additional, Mazzotta, Marco, additional, Ruggeri, Enzo Maria, additional, Pedersini, Rebecca, additional, Valerio, Maria Rosaria, additional, Filomeno, Lorena, additional, Minelli, Mauro, additional, Scavina, Paola, additional, Raffaele, Mimma, additional, Astone, Antonio, additional, De Vita, Roy, additional, Pozzi, Marcello, additional, Riccardi, Ferdinando, additional, Greco, Filippo, additional, Moscetti, Luca, additional, Giordano, Monica, additional, Maugeri-Saccà, Marcello, additional, Zennaro, Alessandro, additional, Botti, Claudio, additional, Pelle, Fabio, additional, Cappelli, Sonia, additional, Cavicchi, Flavia, additional, Vizza, Enrico, additional, Sanguineti, Giuseppe, additional, Tomao, Federica, additional, Cortesi, Enrico, additional, Marchetti, Paolo, additional, Tomao, Silverio, additional, Speranza, Iolanda, additional, Sperduti, Isabella, additional, Ciliberto, Gennaro, additional, and Vici, Patrizia, additional

Published
2023
Full Text
View/download PDF

5. Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2– Metastatic Breast Cancer Patients: What Is the Better Choice?

Author

Fabi, Alessandra, primary, Ciccarese, Mariangela, additional, Scagnoli, Sinome, additional, Russillo, Michelangelo, additional, Schettini, Francesco, additional, Buono, Giuseppe, additional, Lorusso, Vito, additional, Cannita, Katia, additional, Arpino, Grazia, additional, Stani, Simonetta, additional, Palleschi, Michela, additional, Rossello, Rosalba, additional, Sarobba, Giuseppina, additional, Fabbri, Agnese, additional, Giampaglia, Marianna, additional, Pellegrini, Patrizia, additional, Adamo, Vincenzo, additional, Morelli, Francesca, additional, Barberi, Vittoria, additional, Ferretti, Gianluigi, additional, Catania, Giovanna, additional, Pisegna, Simona, additional, Cognetti, Francesco, additional, and Giannarelli, Diana, additional

Published
2021
Full Text
View/download PDF

6. sj-docx-1-tam-10.1177_17588359211059873 ��� Supplemental material for PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting

Author

Pizzuti, Laura, Krasniqi, Eriseld, Sperduti, Isabella, Barba, Maddalena, Gamucci, Teresa, Mauri, Maria, Veltri, Enzo Maria, Meattini, Icro, Berardi, Rossana, Di Lisa, Francesca Sofia, Natoli, Clara, Pistelli, Mirco, Iezzi, Laura, Risi, Emanuela, D���Ostilio, Nicola, Tomao, Silverio, Ficorella, Corrado, Cannita, Katia, Riccardi, Ferdinando, Cassano, Alessandra, Bria, Emilio, Fabbri, Maria Agnese, Mazzotta, Marco, Barchiesi, Giacomo, Botticelli, Andrea, D���Auria, Giuliana, Ceribelli, Anna, Michelotti, Andrea, Russo, Antonio, Salimbeni, Beatrice Taurelli, Sarobba, Giuseppina, Giotta, Francesco, Paris, Ida, Saltarelli, Rosa, Marinelli, Daniele, Corsi, Domenico, Capomolla, Elisabetta Maria, Sini, Valentina, Moscetti, Luca, Mentuccia, Lucia, Tonini, Giuseppe, Raffaele, Mimma, Marchetti, Luca, Minelli, Mauro, Ruggeri, Enzo Maria, Scavina, Paola, Bacciu, Olivia, Salesi, Nello, Livi, Lorenzo, Tinari, Nicola, Grassadonia, Antonino, Fedele Scinto, Angelo, Rossi, Rosalinda, Valerio, Maria Rosaria, Landucci, Elisabetta, Stani, Simonetta, Fratini, Beatrice, Maugeri-Sacc��, Marcello, De Tursi, Michele, Maione, Angela, Santini, Daniele, Orlandi, Armando, Lorusso, Vito, Cortesi, Enrico, Sanguineti, Giuseppe, Pinnar��, Paola, Cappuzzo, Federico, Landi, Lorenza, Botti, Claudio, Tomao, Federica, Cappelli, Sonia, Bon, Giulia, Pelle, Fabio, Cavicchi, Flavia, Fiorio, Elena, Foglietta, Jennifer, Scagnoli, Simone, Marchetti, Paolo, Ciliberto, Gennaro, and Vici, Patrizia

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tam-10.1177_17588359211059873 for PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting by Laura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, Maddalena Barba, Teresa Gamucci, Maria Mauri, Enzo Maria Veltri, Icro Meattini, Rossana Berardi, Francesca Sofia Di Lisa, Clara Natoli, Mirco Pistelli, Laura Iezzi, Emanuela Risi, Nicola D���Ostilio, Silverio Tomao, Corrado Ficorella, Katia Cannita, Ferdinando Riccardi, Alessandra Cassano, Emilio Bria, Maria Agnese Fabbri, Marco Mazzotta, Giacomo Barchiesi, Andrea Botticelli, Giuliana D���Auria, Anna Ceribelli, Andrea Michelotti, Antonio Russo, Beatrice Taurelli Salimbeni, Giuseppina Sarobba, Francesco Giotta, Ida Paris, Rosa Saltarelli, Daniele Marinelli, Domenico Corsi, Elisabetta Maria Capomolla, Valentina Sini, Luca Moscetti, Lucia Mentuccia, Giuseppe Tonini, Mimma Raffaele, Luca Marchetti, Mauro Minelli, Enzo Maria Ruggeri, Paola Scavina, Olivia Bacciu, Nello Salesi, Lorenzo Livi, Nicola Tinari, Antonino Grassadonia, Angelo Fedele Scinto, Rosalinda Rossi, Maria Rosaria Valerio, Elisabetta Landucci, Simonetta Stani, Beatrice Fratini, Marcello Maugeri-Sacc��, Michele De Tursi, Angela Maione, Daniele Santini, Armando Orlandi, Vito Lorusso, Enrico Cortesi, Giuseppe Sanguineti, Paola Pinnar��, Federico Cappuzzo, Lorenza Landi, Claudio Botti, Federica Tomao, Sonia Cappelli, Giulia Bon, Fabio Pelle, Flavia Cavicchi, Elena Fiorio, Jennifer Foglietta, Simone Scagnoli, Paolo Marchetti, Gennaro Ciliberto and Patrizia Vici in Therapeutic Advances in Medical Oncology

Published
2021
Full Text
View/download PDF

7. PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting

Author

Pizzuti, Laura, primary, Krasniqi, Eriseld, additional, Sperduti, Isabella, additional, Barba, Maddalena, additional, Gamucci, Teresa, additional, Mauri, Maria, additional, Veltri, Enzo Maria, additional, Meattini, Icro, additional, Berardi, Rossana, additional, Di Lisa, Francesca Sofia, additional, Natoli, Clara, additional, Pistelli, Mirco, additional, Iezzi, Laura, additional, Risi, Emanuela, additional, D’Ostilio, Nicola, additional, Tomao, Silverio, additional, Ficorella, Corrado, additional, Cannita, Katia, additional, Riccardi, Ferdinando, additional, Cassano, Alessandra, additional, Bria, Emilio, additional, Fabbri, Maria Agnese, additional, Mazzotta, Marco, additional, Barchiesi, Giacomo, additional, Botticelli, Andrea, additional, D’Auria, Giuliana, additional, Ceribelli, Anna, additional, Michelotti, Andrea, additional, Russo, Antonio, additional, Salimbeni, Beatrice Taurelli, additional, Sarobba, Giuseppina, additional, Giotta, Francesco, additional, Paris, Ida, additional, Saltarelli, Rosa, additional, Marinelli, Daniele, additional, Corsi, Domenico, additional, Capomolla, Elisabetta Maria, additional, Sini, Valentina, additional, Moscetti, Luca, additional, Mentuccia, Lucia, additional, Tonini, Giuseppe, additional, Raffaele, Mimma, additional, Marchetti, Luca, additional, Minelli, Mauro, additional, Ruggeri, Enzo Maria, additional, Scavina, Paola, additional, Bacciu, Olivia, additional, Salesi, Nello, additional, Livi, Lorenzo, additional, Tinari, Nicola, additional, Grassadonia, Antonino, additional, Fedele Scinto, Angelo, additional, Rossi, Rosalinda, additional, Valerio, Maria Rosaria, additional, Landucci, Elisabetta, additional, Stani, Simonetta, additional, Fratini, Beatrice, additional, Maugeri-Saccà, Marcello, additional, De Tursi, Michele, additional, Maione, Angela, additional, Santini, Daniele, additional, Orlandi, Armando, additional, Lorusso, Vito, additional, Cortesi, Enrico, additional, Sanguineti, Giuseppe, additional, Pinnarò, Paola, additional, Cappuzzo, Federico, additional, Landi, Lorenza, additional, Botti, Claudio, additional, Tomao, Federica, additional, Cappelli, Sonia, additional, Bon, Giulia, additional, Pelle, Fabio, additional, Cavicchi, Flavia, additional, Fiorio, Elena, additional, Foglietta, Jennifer, additional, Scagnoli, Simone, additional, Marchetti, Paolo, additional, Ciliberto, Gennaro, additional, and Vici, Patrizia, additional

Published
2021
Full Text
View/download PDF

10. Abstract P5-11-18: Real-world evidence of efficacy and activity of palbociclib plus endocrine therapy and post-progression treatments in HR+/HER2- metastatic breast cancer patients: The PALPract study

Author

Fabi, Alessandra, primary, Russillo, Michelangelo, additional, Ciccarese, Mariangela, additional, Scagnoli, Simone, additional, Schettini, Francesco, additional, Buono, Giuseppe, additional, Russo, Vito Lo, additional, Arpino, Grazia, additional, Rossella, Rosalba, additional, Sarobba, Giuseppina, additional, Giampaglia, Marianna, additional, Pellegrini, Patrizia, additional, Stani, Simonetta, additional, Palleschi, Michela, additional, Adamo, Vincenzo, additional, Morelli, Francesca, additional, Fabbri, Maria Agnese, additional, Nistico, Cecilia, additional, Ferretti, Gianluigi, additional, Catania, Giovanna, additional, Pisegna, Simona, additional, Giannarelli, Diana, additional, and Cognetti, Francesco, additional

Published
2020
Full Text
View/download PDF

12. Efficacy of Thalidomide in recurrent high grade gliomas

Author

Fanelli, Massimo, Morabito, Alessandro, Gattuso, Domenico, Vitale, Stefano, Capaccetti, Barbara, Longo, Raffaele, Stani, Simonetta Chiara, Magnani, Elena, Bonginelli, Paola, and Gasparini, Giampietro

Published
2002

18. Efficacy and safety of T-DM1 in the ‘common-practice’ of HER2+ advanced breast cancer setting: a multicenter study

Author

Fabi, Alessandra, primary, De Laurentiis, Michelino, additional, Caruso, Michele, additional, Valle, Enrichetta, additional, Moscetti, Luca, additional, Santini, Daniele, additional, Cannita, Katia, additional, Carbognin, Luisa, additional, Ciccarese, Mariangela, additional, Rossello, Rosalba, additional, Arpino, Grazia, additional, Leonardi, Vita, additional, Montemurro, Filippo, additional, La Verde, Nicla, additional, Generali, Daniele, additional, Zambelli, Alberto, additional, Scandurra, Giuseppa, additional, Russillo, Michelangelo, additional, Paris, Ida, additional, D'Ottavio, Anna Maria, additional, Filippelli, Gianfranco, additional, Giampaglia, Marianna, additional, Stani, Simonetta, additional, Fabbri, Agnese, additional, Alesini, Daniele, additional, Cianniello, Daniela, additional, Giannarelli, Diana, additional, and Cognetti, Francesco, additional

Published
2017
Full Text
View/download PDF

19. Real-life effectiveness of T-DM1 in heavily pretreated HER2-positive advanced breast cancer patients: An Italian observational study.

Author

Fabi, Alessandra, primary, Cannita, Katia, additional, Ferretti, Gianluigi, additional, Ciccarese, Mariangela, additional, Arpino, Grazia, additional, Montemurro, Filippo, additional, La Verde, Nicla Maria, additional, Generali, Daniele Giulio, additional, Scandurra, Giuseppina, additional, Filippelli, Gianfranco, additional, Russillo, Michelangelo, additional, Paris, Ida, additional, Stani, Simonetta, additional, Fabbri, Agnese, additional, Minelli, Mauro, additional, Cognetti, Francesco, additional, and Giannarelli, Diana, additional

Published
2016
Full Text
View/download PDF

21. The Combination of the Selective Cyclooxygenase-2 Inhibitor Celecoxib with Weekly Paclitaxel Is a Safe and Active Second-Line Therapy for Non-Small Cell Lung Cancer

Author

Gasparini, Giampietro, primary, Meo, Sabrina, additional, Cornelia, Giuseppe, additional, Stani, Simonetta Chiara, additional, Mariani, Luigi, additional, Gamucci, Teresa, additional, Avallone, Antonio, additional, Vullo, Salvatore Lo, additional, Mansueto, Giovanni, additional, Bonginelli, Paola, additional, Gattuso, Domenico, additional, and Gion, Massimo, additional

Published
2005
Full Text
View/download PDF

22. Second line treatment of antiangiogenic therapy with celecoxib and weekly paclitaxel for advanced non-small cell lung cancer (NSCLC)

Author

Stani, Simonetta Chiara, primary, Sarmiento, Roberta, additional, Mansueto, Giovanni, additional, Bonginelli, Paola, additional, Comella, Giovanni, additional, Ferrau, Francesco, additional, Magnani, Elena, additional, Carillio, Guido, additional, Sciacca, Venerina, additional, and Gasparini, Giampietro, additional

Published
2003
Full Text
View/download PDF

26. Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer

Author

Bidoli, Paolo, Stani, Simonetta C., Mariani, Luigi, Candis, Daniela De, Cortinovis, Diego, Aglione, Stefania, Zilembo, Nicoletta, Toffolatti, Luisa, Formisano, Barbara, and Bajetta, Emilio

Subjects
*PLATINUM, *ANTINEOPLASTIC agents, *SMALL cell lung cancer, *TOXICITY testing
Abstract

Purpose: Oxaliplatin (OHP) is a new platinum antineoplastic, while gemcitabine (GEM) is one of the most active drugs against non-small cell carcinoma (NSCLC). The OHP/GEM combination is interesting because the drugs have different mechanisms of action and toxicity profiles. The primary endpoint of this study was to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of OHP/GEM combination in non-small cell carcinoma of the lung. Methods: Patients with relapsed NSCLC were treated with fixed dose i.v. GEM (1250 mg/m2) on days 1 and 8; followed on day 1 by i.v. OHP over 3 h, starting from 70 mg/m2 with 20 mg/m2 increments, up to 130 mg/m2. We enrolled 19 patients with eastern cooperative oncology group (ECOG) status 0/1=13/6; male/female=13/6. All had received first-line and four second-line chemotherapy. Results: Four patients dropped out. At dose level 2, one patient died of pulmonary embolism; at level 3, two patients died of disease progression. One patient at level 3, refused to continue treatment after allergic reaction (high fever episode) during infusion of third cycle. Fifteen patients were evaluable for toxicity and response. According to a priori statistical considerations, three patients in each of the first three treatment levels and six in the last level were evaluable. No G3–4 toxicity was observed at levels 1 and 2. G3 neutropenia and anemia occurred in 8% of cycles at level 3. Six patients entered level 4 (OHP 130 mg/m2) with 22 courses delivered: G3–4 neutropenia occurred in 9%, G1–2 thrombocytopenia in 18%; other toxicities were mainly limited to G1–2 flu-like syndrome in about one third of patients and G1–2 nausea and vomiting in 5% of courses. There was no myelo-DLT at the highest dose level. There was no neurotoxicity at any level. Treatment was delayed in 12% and dose reduced in 26% of courses. There were 2/15 PR. Conclusions: MTD was not reached. OHP and GEM can probably be administered safely at 130 and 1250 mg/m2, respectively, as first-line therapy. The schedule is being used in a phase II trial. [Copyright &y& Elsevier]

Published
2004
Full Text
View/download PDF

27. Post-Progression Treatments after Palbociclib plus Endocrine Therapy in HR+/HER2– Metastatic Breast Cancer Patients: What Is the Better Choice?

Author

Alessandra Fabi, Mariangela Ciccarese, Sinome Scagnoli, Michelangelo Russillo, Francesco Schettini, Giuseppe Buono, Vito Lorusso, Katia Cannita, Grazia Arpino, Simonetta Stani, Michela Palleschi, Rosalba Rossello, Giuseppina Sarobba, Agnese Fabbri, Marianna Giampaglia, Patrizia Pellegrini, Vincenzo Adamo, Francesca Morelli, Vittoria Barberi, Gianluigi Ferretti, Giovanna Catania, Simona Pisegna, Francesco Cognetti, Diana Giannarelli, Fabi, Alessandra, Ciccarese, Mariangela, Scagnoli, Sinome, Russillo, Michelangelo, Schettini, Francesco, Buono, Giuseppe, Lorusso, Vito, Cannita, Katia, Arpino, Grazia, Stani, Simonetta, Palleschi, Michela, Rossello, Rosalba, Sarobba, Giuseppina, Fabbri, Agnese, Giampaglia, Marianna, Pellegrini, Patrizia, Adamo, Vincenzo, Morelli, Francesca, Barberi, Vittoria, Ferretti, Gianluigi, Catania, Giovanna, Pisegna, Simona, Cognetti, Francesco, and Giannarelli, Diana

Subjects
Cancer Research, Oncology, General Medicine
Abstract

Background: To date, a consensus has not yet been reached about the therapy sequence after disease progression (PD) on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer (MBC). Objectives: The present study assesses, in a real-world setting, the activity of different subsequent therapies in patients who experienced a PD on palbociclib (P) + endocrine therapy (ET), to evaluate the best therapy sequence. Methods: This is a multicenter retrospective observational study. Records of consecutive HR+/HER2- MBC patients from January 2017 to May 2019 were reviewed. The primary endpoint was the evaluation of progression-free survival (PFS) according to subsequent treatment lines after progression on P+ET. Toxicity data were also collected. Results: The outcomes were analyzed in 89 MBC patients that had progressed on previous P+ET: 17 patients were on hormone therapy (HT) and 31 patients on chemotherapy (CT) as second-line treatments; seven patients were on HT and 34 on CT as third-line therapies. PFS of patients treated with HT as second-line therapy is significantly improved when compared with patients treated with CT (p=0.01). Considering third-line settings, the difference in PFS was not statistically different between HT and CT. A better outcome in terms of toxicity is observed among HT patients for both second- and third-line therapies. Conclusions: patients who were progressive on P+ET could still benefit from a subsequent ET. In patients who experienced a good efficacy from prior ET, without visceral metastatic sites, HT seems the most suitable option, when compared to CT, also in terms of safety.

Published
2021

28. Efficacy and safety of T-DM1 in the ‘common-practice’ of HER2+ advanced breast cancer setting: a multicenter study

Author

Daniele Santini, Simonetta Stani, Alberto Zambelli, Alessandra Fabi, Vita Leonardi, Michelangelo Russillo, Daniele Alesini, Daniela Cianniello, Grazia Arpino, Luisa Carbognin, Diana Giannarelli, Michele Caruso, Marianna Giampaglia, Mariangela Ciccarese, Giuseppa Scandurra, Daniele Generali, Rosalba Rossello, E. Valle, A. Fabbri, Gianfranco Filippelli, Filippo Montemurro, Ida Paris, Katia Cannita, Luca Moscetti, Nicla La Verde, A.M. D'Ottavio, Michelino De Laurentiis, Francesco Cognetti, Fabi, Alessandra, DE LAURENTIIS, Michelino, Caruso, Michele, Valle, Enrichetta, Moscetti, Luca, Santini, Daniele, Cannita, Katia, Carbognin, Luisa, Ciccarese, Mariangela, Rossello, Rosalba, Arpino, Grazia, Leonardi, Vita, Montemurro, Filippo, La Verde, Nicla, Generali, Daniele, Zambelli, Alberto, Scandurra, Giuseppa, Russillo, Michelangelo, Paris, Ida, D'Ottavio, Anna Maria, Filippelli, Gianfranco, Giampaglia, Marianna, Stani, Simonetta, Fabbri, Agnese, Alesini, Daniele, Cianniello, Daniela, Giannarelli, Diana, Cognetti, Francesco, De Laurentiis, Michelino, and D’Ottavio, Anna Maria

Subjects
musculoskeletal diseases, 0301 basic medicine, Oncology, congenital, hereditary, and neonatal diseases and abnormalities, medicine.medical_specialty, medicine.medical_treatment, Population, ado-trastuzumab emtansine, HER2, metastatic breast cancer, taxane, trastuzumab, Lapatinib, Metastasis, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, Trastuzumab, Internal medicine, medicine, skin and connective tissue diseases, education, neoplasms, education.field_of_study, Taxane, business.industry, Cancer, medicine.disease, Metastatic breast cancer, 030104 developmental biology, 030220 oncology & carcinogenesis, Clinical Research Paper, business, medicine.drug
Abstract

Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive, metastatic breast cancer (mBC). The aim of this ‘field-practice’ study was to investigate the efficacy and safety of T-DM1, focusing on treatment line, previous lapatinib treatment and patterns of metastasis. Three hundred and three patients with HER2-positive mBC who received T-DM1 were identified by reviewing the medical records of 24 Italian Institutions. One hundred fourty-nine (49%) and 264 (87%) had received prior hormonal treatment and/or anti-HER2 targeted therapy, respectively. Particularly, 149 patients had been previously treated with lapatinib. The objective response rate (ORR) was 36.2%, and 44.5% when T-DM1 was administrated as second-line therapy. Considering only patients with liver metastases, the ORR was 44.4%. The median progression-free survival (PFS) was 7.0 months in the overall population, but it reached 9.0 and 12.0 months when TDM-1 was administered as second- and third-line treatment, respectively. In conclusion, in this ‘real-word’ study evaluating the effects of T-DM1 in patients with HER2-positive mBC who progressed on prior anti-HER2 therapies, we observed a clinically-relevant benefit in those who had received T-DM1 in early metastatic treatment-line and in subjects previously treated with lapatinib.

Published
2017

29. Antiangiogenic agents.

Author

Stani SC, Capaccetti B, Bonginelli P, Sarmiento R, De Sio L, Fanelli M, and Gasparini G

Subjects
Carcinoma, Non-Small-Cell Lung drug therapy, Clinical Trials as Topic, Cyclooxygenase 2, Enzyme Inhibitors therapeutic use, Epidermal Growth Factor antagonists & inhibitors, Humans, Isoenzymes antagonists & inhibitors, Lung Neoplasms drug therapy, Matrix Metalloproteinase Inhibitors, Membrane Proteins, Prostaglandin-Endoperoxide Synthases, Receptor, ErbB-2 antagonists & inhibitors, Angiogenesis Inhibitors therapeutic use, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung blood supply, Lung Neoplasms blood supply, Neovascularization, Pathologic drug therapy
Published
2002

Catalog

Books, media, physical & digital resources
See catalog results